Keros Therapeutics, Inc. stock is up 21.04% since 30 days ago. The next earnings date is Mar 1, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 3 December’s closed higher than November. In the last 3 Unusual Options Trades, there were 1 CALL, 2 PUTs. 100% of analysts rate it a buy.
Keros Therapeutics, Inc. focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia.